Search

Your search keyword '"Distler, J. H."' showing total 16 results
Start Over Author "Distler, J. H." Publisher bmj publishing group
16 results on '"Distler, J. H."'

1. PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE

Author

Sarbu, A.C., Guler, S., Stadler, O., Allanore, Y., Bernardino, V., Distler, J. H. W., Gabrielli, A., Hoffmann-Vold, A. M., Matucci-Cerinic, M., Müller-Ladner, U., Ortiz-Santamaria, V., Rednic, S., Riccieri, V., Smith, V., Ullman, S., Walker, U., Geiser, T., Distler, O., Maurer, B., and Kollert, F.

Subjects
610 Medicine & health
Published
2022
Full Text
View/download PDF

2. EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT

Author

Kuster, S., Jordan, S., Elhai, M. D., Held, U., Steigmiller, K., Bruni, C., Iannone, F., Vettori, S., Siegert, E., Rednic, S., Codullo, V., Airo, P., Braun-Moscovici, Y., Hunzelmann, N., Salvador, M. J., Riccieri, V., Gheorghiu, A. M., Alegre Sancho, J. J., Romanowska-Prochnicka, K., Castellvi, I., Koetter, I., Truchetet, M. E., Lopez-Longo, F. J., Novikov, P., Giollo, A., Shirai, Y., Belloli, L., Zanatta, E., Hachulla, E., Smith, V., Denton, C., Ionescu, R., Schmeiser, T., Distler, J. H. W., Gabrielli, A., Hoffmann-Vold, A. M., Kuwana, M., Allanore, Y., Distler, O., Kuster, S., Jordan, S., Elhai, M. D., Held, U., Steigmiller, K., Bruni, C., Iannone, F., Vettori, S., Siegert, E., Rednic, S., Codullo, V., Airo, P., Braun-Moscovici, Y., Hunzelmann, N., Salvador, M. J., Riccieri, V., Gheorghiu, A. M., Alegre Sancho, J. J., Romanowska-Prochnicka, K., Castellvi, I., Koetter, I., Truchetet, M. E., Lopez-Longo, F. J., Novikov, P., Giollo, A., Shirai, Y., Belloli, L., Zanatta, E., Hachulla, E., Smith, V., Denton, C., Ionescu, R., Schmeiser, T., Distler, J. H. W., Gabrielli, A., Hoffmann-Vold, A. M., Kuwana, M., Allanore, Y., and Distler, O.

Published
2021

3. PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING

Author

Bruni, C., Heidenreich, S., Duenas, A., Hoffmann-Vold, A. M., Gabrielli, A., Allanore, Y., Chatelus, E., Distler, J. H. W., Hachulla, E., Hsu, V., Hunzelmann, N., Khanna, D., Truchetet, M. E., Walker, U., Alves, M., Schoof, N., Saketkoo, L. A., Distler, O., Bruni, C., Heidenreich, S., Duenas, A., Hoffmann-Vold, A. M., Gabrielli, A., Allanore, Y., Chatelus, E., Distler, J. H. W., Hachulla, E., Hsu, V., Hunzelmann, N., Khanna, D., Truchetet, M. E., Walker, U., Alves, M., Schoof, N., Saketkoo, L. A., and Distler, O.

Published
2021

4. NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY

Author

Lopez-Isac, E., Acosta-Herrera, M., Assassi, S., Simeon, C. P., Carreira, P. E., Castellvi, I., Ortego-Centeno, N., Beretta, L., Lunardi, C., Gabrielli, A., Moroncini, G., Hunzelmann, N., Witte, T., Distler, J. H., Franke, A., Voskuyl, A. E., de Vries-Bouwstra, J., Wijmenga, C., Hesselstrand, R., Nordin, A., Hoffmann-Vold, A. -M., Herrick, A., Worthington, J., Denton, C. P., Brown, M. A., Allanore, Y., Radstake, T. R., Fonseca, C., Mayes, M. D., Martin, J., Lopez-Isac, E., Acosta-Herrera, M., Assassi, S., Simeon, C. P., Carreira, P. E., Castellvi, I., Ortego-Centeno, N., Beretta, L., Lunardi, C., Gabrielli, A., Moroncini, G., Hunzelmann, N., Witte, T., Distler, J. H., Franke, A., Voskuyl, A. E., de Vries-Bouwstra, J., Wijmenga, C., Hesselstrand, R., Nordin, A., Hoffmann-Vold, A. -M., Herrick, A., Worthington, J., Denton, C. P., Brown, M. A., Allanore, Y., Radstake, T. R., Fonseca, C., Mayes, M. D., and Martin, J.

Published
2018

5. DIFFUSING CAPACITY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS

Author

Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Worm, M., Sunderkoetter, C., Schmalzing, M., Kreuter, A., Gunther, C., Susok, L., Zeidler, G., Koetter, I., Mueller-Ladner, U., Krieg, T., Juche, A., Schmeiser, T., Riemekasten, G., Aberer, E., Gaebelein-Wissing, N., Distler, J. H. W., Sardy, M., Pfeiffer, C., Kuhr, K., Hunzelmann, N., Bonella, F., Kreuter, M., Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Worm, M., Sunderkoetter, C., Schmalzing, M., Kreuter, A., Gunther, C., Susok, L., Zeidler, G., Koetter, I., Mueller-Ladner, U., Krieg, T., Juche, A., Schmeiser, T., Riemekasten, G., Aberer, E., Gaebelein-Wissing, N., Distler, J. H. W., Sardy, M., Pfeiffer, C., Kuhr, K., Hunzelmann, N., Bonella, F., and Kreuter, M.

Published
2017

6. EVALUATION OF FREQUENCY AND TYPE OF PHYSICAL THERAPY IN MORE THAN 3400 PATIENTS WITH SYSTEMIC SCLEROSIS

Author

Belz, D., Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Worm, M., Sunderkoetter, C., Schmalzing, M., Kreuter, A., Gunther, C., Susok, L., Zeidler, G., Koetter, I., Mueller-Ladner, U., Krieg, T., Juche, A., Schmeiser, T., Riemekasten, G., Aberer, E., Gaebelein-Wissing, N., Distler, J. H. W., Sardy, M., Pfeiffer, C., Kuhr, K., Hunzelmann, N., Belz, D., Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Worm, M., Sunderkoetter, C., Schmalzing, M., Kreuter, A., Gunther, C., Susok, L., Zeidler, G., Koetter, I., Mueller-Ladner, U., Krieg, T., Juche, A., Schmeiser, T., Riemekasten, G., Aberer, E., Gaebelein-Wissing, N., Distler, J. H. W., Sardy, M., Pfeiffer, C., Kuhr, K., and Hunzelmann, N.

Published
2017

7. DISEASE PROGRESSION IN 282 PATIENTS WITH UNDIFFERENTIATED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA

Author

Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Susok, L., Distler, J. H. W., Juche, A., Worm, M., Gil, H. C., Schmeiser, T., Zeidler, G., Gaebelein-Wissing, N., Krieg, T., Sunderkoetter, C., Kreuter, A., Sardy, M., Riemekasten, G., Mueller-Ladner, U., Frerix, M., Kuhr, K., Hunzelmann, N., Moinzadeh, P., Blank, N., Siegert, E., Henes, J., Susok, L., Distler, J. H. W., Juche, A., Worm, M., Gil, H. C., Schmeiser, T., Zeidler, G., Gaebelein-Wissing, N., Krieg, T., Sunderkoetter, C., Kreuter, A., Sardy, M., Riemekasten, G., Mueller-Ladner, U., Frerix, M., Kuhr, K., and Hunzelmann, N.

Published
2016

9. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research

Author

Beyer, C, Distler, J H W, Allanore, Y, Aringer, M, Avouac, J, Czirják, L, Cutolo, M, Damjanov, N, Del Galdo, F, Fligelstone, K, Guiducci, S, Kowal-Bielecka, O, van Laar, J M, Martucci-Cerinic, M, Müller-Ladner, U, Riemekasten, G, Tarner, I H, Tyndall, A, Kennedy, A T, Valentini, G, Vettori, S, Walker, U A, Denton, C, Distler, O, Beyer, C, Distler, J H W, Allanore, Y, Aringer, M, Avouac, J, Czirják, L, Cutolo, M, Damjanov, N, Del Galdo, F, Fligelstone, K, Guiducci, S, Kowal-Bielecka, O, van Laar, J M, Martucci-Cerinic, M, Müller-Ladner, U, Riemekasten, G, Tarner, I H, Tyndall, A, Kennedy, A T, Valentini, G, Vettori, S, Walker, U A, Denton, C, and Distler, O

Abstract

The European League Against Rheumatism Scleroderma Trials and Research Group (EUSTAR) has established an online database with clinical data of currently more than 8200 patients with systemic sclerosis (SSc). In addition to clinical research, EUSTAR fosters biomolecular studies to develop novel biomarkers and therapies for SSc. High-quality biospecimens are the basis for successful biomolecular studies. The EUSTAR biobanking group has therefore developed recommendations to standardise the collection, storage and distribution of SSc biospecimens at EUSTAR centres. These recommendations consider the scientific challenges associated with biomolecular research in SSc and the organisational requirements of EUSTAR. They were approved by the EUSTAR executive committee as well as the EUSTAR board. Once they become effective, these recommendations will be the basis for international EUSTAR studies with large numbers of SSc biospecimens. These recommendations might also be followed by other SSc consortia to enable exchange of biosamples between different SSc initiatives and might serve as a template for biobanking initiatives in other rheumatic diseases.

Published
2011

10. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease

Author

Distler, J H W, Strapatsas, T, Huscher, D, Dees, C, Akhmetshina, A, Kiener, H P, Tarner, I H, Maurer, B, Walder, M, Michel, B, Gay, S, Smolen, J S, Müller-Ladner, U, Schett, G, Distler, O, Distler, J H W, Strapatsas, T, Huscher, D, Dees, C, Akhmetshina, A, Kiener, H P, Tarner, I H, Maurer, B, Walder, M, Michel, B, Gay, S, Smolen, J S, Müller-Ladner, U, Schett, G, and Distler, O

Abstract

/st> Molecular factors modulating angiogenic responses are dysregulated in patients with MCTD and SSc with increases of VEGF in MCTD and SSc and selective upregulation of endostatin in MCTD. Furthermore, high serum levels of VEGF might characterise patients with MCTD with a more severe course of the disease with increased prevalence of PAH and myositis.

Published
2011

11. EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells

Author

Distler, J H W, Allanore, Y, Avouac, J, Giacomelli, R, Guiducci, S, Moritz, F, Akhmetshina, A, Walker, U A, Gabrielli, A, Müller-Ladner, U, Tyndall, A, Matucci-Cerinic, M, Distler, O, Distler, J H W, Allanore, Y, Avouac, J, Giacomelli, R, Guiducci, S, Moritz, F, Akhmetshina, A, Walker, U A, Gabrielli, A, Müller-Ladner, U, Tyndall, A, Matucci-Cerinic, M, and Distler, O

Abstract

Systemic sclerosis (SSc) is characterised by a progressive microangiopathy that contributes significantly to the morbidity of patients with SSc. Besides insufficient angiogenesis, defective vasculogenesis with altered numbers of endothelial precursor cells (EPCs) might also contribute to the vascular pathogenesis of SSc. However, different protocols for isolation, enrichment, culture and quantification of EPCs are currently used, which complicate comparison and interpretation of the results from different studies. The aim of the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) group expert panel was to provide recommendations for standardisation of future research on EPCs. Consensus statements and recommendations were developed in a face to face meeting by an expert panel of the basic science working group of EUSTAR. The findings were: cardiovascular risk factors and medications such as statins should be described in detail. A detailed description of methods considering isolation, culture, enrichment and detection of EPCs should be given. For in vitro culture of EPCs, no protocol has been shown to be superior to another, but coating with laminin and type IV collagen would resemble most closely the situation in vivo. The endothelial phenotype should be confirmed in all in vitro cultures at the end of the culture period. We recommend using CD133, vascular endothelial growth factor type 2 receptor (VEGFR2) and CD34 in combination with a viability marker for quantification of EPCs in the blood. Finally, exact standard operating procedures for fluorescence-activated cell sorting (FACS) analysis are given that should be strictly followed. In summary, the EUSTAR recommendations will help to unify EPC research and allow better comparison between the results of different studies.

Published
2009

12. Interleukin-1 is essential for systemic inflammatory bone loss.

Author

Polzer, K, Joosten, L, Gasser, J, Distler, J H, Ruiz, G, Baum, W, Redlich, K, Bobacz, K, Smolen, J S, van den Berg, W, Schett, G, and Zwerina, J

Abstract

Objectives: Chronic inflammation is a major risk factor for systemic bone loss leading to osteoporotic fracture and substantial morbidity and mortality. Inflammatory cytokines, particularly tumour necrosis factor (TNF) and interleukin-1 (IL1), are thought to play a key role in the pathogenesis of inflammation-induced bone loss, but their exact roles are yet to be determined. Methods: To determine whether TNF directly triggers bone loss or requires IL1, human TNFα mice (hTNFtg) were crossed with mice lacking IL1α and IL1β (IL1hTNFtg). Systemic bone architecture was evaluated using CT scanning, static and dynamic bone histomorphometry and serum markers of bone metabolism. Results: hTNFtg mice developed severe bone loss accompanied by a severe distortion of bone microarchitecture. Bone trabeculae were thinner and decreased in numbers, resulting in increased trabecular separation. Histomorphometric analyses revealed strongly increased bone resorption in hTNFtg mice compared with wild-type mice. In contrast, IL1hTNFtg mice were fully protected from systemic bone loss despite still developing inflammation in their joints. Lack of IL1 completely reversed increased osteoclast formation and bone resorption in hTNFtg mice and the increased levels of RANKL in these mice. Structural parameters and osteoclast and osteoblast numbers were indistinguishable from wild-type mice. Conclusions: These data indicate that IL1 is essential for TNF-mediated bone loss. Despite TNF-mediated inflammatory arthritis, systemic bone is fully protected by the absence of IL1, which suggests that IL1 is an essential mediator of inflammatory osteopenia. [ABSTRACT FROM PUBLISHER]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results